- Home
- AYTU vs TENX Comparison
AYTU vs TENX Comparison
Compare AYTU & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AYTU
- TENX
- Stock Information
- Founded
- AYTU N/A
- TENX 1967
- Country
- AYTU United States
- TENX United States
- Employees
- AYTU N/A
- TENX N/A
- Industry
- AYTU Biotechnology: Pharmaceutical Preparations
- TENX Biotechnology: Pharmaceutical Preparations
- Sector
- AYTU Health Care
- TENX Health Care
- Exchange
- AYTU Nasdaq
- TENX Nasdaq
- Market Cap
- AYTU 10.7M
- TENX 11.4M
- IPO Year
- AYTU N/A
- TENX N/A
- Fundamental
- Price
- AYTU $1.51
- TENX $4.88
- Analyst Decision
- AYTU
- TENX Strong Buy
- Analyst Count
- AYTU 0
- TENX 4
- Target Price
- AYTU N/A
- TENX $20.67
- AVG Volume (30 Days)
- AYTU 45.2K
- TENX 68.7K
- Earning Date
- AYTU 11-13-2024
- TENX 11-13-2024
- Dividend Yield
- AYTU N/A
- TENX N/A
- EPS Growth
- AYTU N/A
- TENX N/A
- EPS
- AYTU N/A
- TENX N/A
- Revenue
- AYTU $79,759,000.00
- TENX N/A
- Revenue This Year
- AYTU N/A
- TENX N/A
- Revenue Next Year
- AYTU $2.35
- TENX N/A
- P/E Ratio
- AYTU N/A
- TENX N/A
- Revenue Growth
- AYTU N/A
- TENX N/A
- 52 Week Low
- AYTU $1.41
- TENX $2.77
- 52 Week High
- AYTU $3.45
- TENX $33.44
- Technical
- Relative Strength Index (RSI)
- AYTU 26.32
- TENX 61.00
- Support Level
- AYTU $1.41
- TENX $4.50
- Resistance Level
- AYTU $1.63
- TENX $5.09
- Average True Range (ATR)
- AYTU 0.21
- TENX 0.24
- MACD
- AYTU -0.01
- TENX -0.03
- Stochastic Oscillator
- AYTU 11.98
- TENX 66.98
About AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.
About TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.